Use of a new acellular dermal matrix for treatment of nonhealing wounds in the lower extremities of patients with diabetes.

Introduction: Acellular dermal matrices (ADMs) have successfully been used in the treatment of nonhealing wounds in patients with diabetes.

Methods: A new decellularized biological scaffold derived from human skin, D-ADM, (DermACELL, LifeNet Health, Virginia Beach, VA), has shown increased cell infiltration, host tissue integration, and vascularization in comparison to other ADMs. This clinical investigation evaluated the wound closing properties of D-ADM on 18 full-thickness lower extremity wounds in 15 patients with diabetes over a period of 12 weeks.

A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures.

Objectives: Recombinant thrombin (rThrombin) is a potential hemostatic alternative to bovine and human plasma-derived thrombin. This report examines the clinical results for the vascular surgery subgroup of patients enrolled in a larger double-blind, randomized, multicenter trial, which evaluated the comparative safety and efficacy of rThrombin and bovine plasma-derived thrombin (bThrombin) when used as adjuncts to surgical hemostasis.

Methods: Data from the 164 vascular patients who underwent either a peripheral arterial bypass (PAB) or arteriovenous graft (AV) procedure are included in this analysis.